Hidradenitis suppurativa (HS) is a chronic inflammatory HS skin disease that most people have never heard of – yet it affects ...

Jeff Stark, MD, vice president and head of immunology, UCB, discusses findings on improved pain management in patients with moderate to severe hidradenitis suppurativa (HS). Treatment with bimekizumab ...

Reduction of draining tunnels sustained to three years: Of patients who had at least one draining tunnel at baseline, 48.2% had none at one year, and 62.9% at three years* – indicating sustained ...

Hidradenitis suppurativa (HS) is a chronic, painful, and debilitating inflammatory skin disease that is associated with systemic manifestations.2 5,26 The main symptoms are nodules, abscesses, and pus ...

ATLANTA, March 8, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies examining ...

At 54 weeks in the STOP-HS1 and STOP-HS2 trials, up to 71.4% of patients taking povorcitinib achieved at least a 50% reduction from baseline in the total abscess and inflammatory ...

Bimekizumab at different dosing intervals was associated with greater IHS4 improvements at week 48 than placebo in patients with HS.

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

The STOP-HS data supported the submission of a New Drug Application (NDA) and Marketing Authorization Application (MAA) for povorcitinib as a treatment for HS which are under review by the U.S. Food ...